GlobeNewswire·Nov 5, 2026, 4:34 PM ET

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

Nkarta, Inc. reported third quarter 2026 financial results with a cash balance of $216.0 million as of September 30, 2026.
Initial clinical data for NKX019 in idiopathic inflammatory myopathy and systemic sclerosis will be presented at ACR Convergence 2026 in Orlando.
Presentations at the conference include an oral presentation on myositis on November 8, a poster on systemic sclerosis on November 9, and an oral safety presentation across autoimmune indications on November 11.
The company expects its current cash and equivalents to fund operations into 2029.
Research and development expenses were $29.5 million for the quarter, while general and administrative expenses were $6.3 million.
The net loss for the third quarter of 2026 was $33.3 million, or $0.45 per share.
Enrollment continues in the Ntrust-1 and Ntrust-2 trials, which evaluate NKX019 in multiple autoimmune diseases including myositis, systemic sclerosis, ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, and primary membranous nephropathy.
Patients in the Ntrust trials are receiving 4 billion cells per dose for three doses, totaling 12 billion cells, across all indications.
Outpatient dosing is currently underway at community-based sites to expand access beyond academic medical centers.
NKX019 is an allogeneic, off-the-shelf CAR-NK cell therapy engineered to target CD19-positive B cells in autoimmune conditions.